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Introduction
Interleukin-1b (IL-1b) plays a key role in the pathogenesis
of systemic juvenile idiopathic arthritis (SJIA). Efficacy and
safety of canakinumab (CAN), a selective, fully human,
anti- IL-1b monoclonal antibody, have been demonstrated
in 2 phase III trials. Here we present 12-week results of a
post-hoc pooled analysis.
Objectives
To evaluate the 12-week efficacy of CAN 4 mg/kg in
treatment naïve patients (pts).
Methods
Data from the 3 trials done as part of the phase III pro-
gram were pooled for this analysis. Pts aged 2-19 yrs with
active SJIA were enrolled and received subcutaneous CAN
4 mg/kg or placebo. The post-hoc analysis presented here
focuses on SJIA response to CAN therapy in the initial
treatment period of a total of 178 CAN-naïve pts. Metho-
dological factors precluded a comparator group, so this
analysis is of a descriptive nature.
Results
At baseline (BL), 94% of pts had intermittent spiking fever
due to SJIA; and 73% were on steroids (mean dose of 0.38
mg/kg/d). In the pooled analysis (N = 178), by Week 2 evi-
dence of profound clinical benefit was observed (Table 1)
with 20% of pts even achieving inactive disease.
The median CRP level of 158 mg/L at BL decreased
by a median of 82% and 94% by weeks 2 and 12,
respectively. Rapid improvements were also observed in
the number of active joints. The median number of
active joints decreased from 10 at BL to 2.5 at Week 2
and 0 at Week 12. Similarly, for joints with limitation of
motion, median values decreased from 9 at BL to 2.5
and 1 at Week 2 and 12, respectively. While 94% pts
had fever due to SJIA at BL, only 13% at Week 2 and
2% at Week 12 had fever. Notably, CAN therapy
resulted in marked improvement in patient reported
outcomes: parent/patient assessment of pain (0-100 mm,
VAS) decreased from a mean of 67 mm at BL to 22
mm at Week 2 and 11 mm at Week 12. The median
CHAQ disability score decreased from 1.8 at BL to 0.6
at Week 2 and 0.3 at Week 12. Between BL and Week
12, the median physicians’ global assessment of SJIA
activity (0-100 mm, VAS) decreased from 70 mm to 3
mm and the parents’/patients’ assessment of overall
well-being improved from 63 mm to 4.5 mm.
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Table 1 Percentage of patients with adapted JIA ACR
(aacr) response and inactive disease
CAN, N = 178



















54 (30%) 50 (28%)
Data from missing patients not shown; aacr response = ACR response level
plus absence of fever
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Conclusion
Based on this post-hoc analysis, response of the SJIA
patients studied for the phase III program of CAN
showed a rapid and clinically important improvement of
their disease by Week 12 of therapy, with an aacr 50
or higher responses reached by the majority of the
CAN-naïve pts within 2 weeks after the initial CAN dose.
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